TD Private Client Wealth LLC Purchases 8,703 Shares of Bristol-Myers Squibb (NYSE:BMY)

TD Private Client Wealth LLC lifted its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 11.9% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 82,008 shares of the biopharmaceutical company’s stock after buying an additional 8,703 shares during the quarter. TD Private Client Wealth LLC’s holdings in Bristol-Myers Squibb were worth $4,243,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Lantz Financial LLC grew its position in Bristol-Myers Squibb by 17.4% in the 2nd quarter. Lantz Financial LLC now owns 11,799 shares of the biopharmaceutical company’s stock valued at $490,000 after purchasing an additional 1,747 shares during the period. Envestnet Portfolio Solutions Inc. lifted its holdings in shares of Bristol-Myers Squibb by 10.0% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 206,709 shares of the biopharmaceutical company’s stock worth $8,585,000 after acquiring an additional 18,741 shares during the last quarter. Cornerstone Wealth Management LLC lifted its holdings in shares of Bristol-Myers Squibb by 11.1% in the 2nd quarter. Cornerstone Wealth Management LLC now owns 17,093 shares of the biopharmaceutical company’s stock worth $710,000 after acquiring an additional 1,701 shares during the last quarter. Baader Bank Aktiengesellschaft purchased a new stake in Bristol-Myers Squibb during the 2nd quarter valued at about $260,000. Finally, SOA Wealth Advisors LLC. raised its position in Bristol-Myers Squibb by 19.4% during the 2nd quarter. SOA Wealth Advisors LLC. now owns 4,662 shares of the biopharmaceutical company’s stock valued at $194,000 after purchasing an additional 759 shares during the last quarter. 76.41% of the stock is owned by institutional investors.

Bristol-Myers Squibb Price Performance

NYSE BMY opened at $56.65 on Thursday. The company has a fifty day simple moving average of $55.72 and a 200 day simple moving average of $49.07. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $61.08. The company has a current ratio of 1.24, a quick ratio of 1.09 and a debt-to-equity ratio of 2.83. The company has a market cap of $114.90 billion, a P/E ratio of -15.78, a P/E/G ratio of 15.93 and a beta of 0.45.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.80 EPS for the quarter, topping analysts’ consensus estimates of $1.49 by $0.31. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. The firm had revenue of $11.89 billion during the quarter, compared to analyst estimates of $11.26 billion. During the same period last year, the company earned $2.00 earnings per share. The company’s revenue was up 8.4% on a year-over-year basis. On average, sell-side analysts predict that Bristol-Myers Squibb will post 0.93 EPS for the current year.

Bristol-Myers Squibb Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, February 3rd. Shareholders of record on Friday, January 3rd will be issued a dividend of $0.62 per share. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. This represents a $2.48 annualized dividend and a yield of 4.38%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently -66.85%.

Analyst Ratings Changes

A number of brokerages recently issued reports on BMY. Citigroup upped their price target on shares of Bristol-Myers Squibb from $55.00 to $60.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 12th. TD Cowen raised their price target on Bristol-Myers Squibb from $53.00 to $59.00 and gave the company a “hold” rating in a report on Monday, October 7th. Daiwa Capital Markets upgraded Bristol-Myers Squibb from a “neutral” rating to an “outperform” rating in a research report on Wednesday, November 13th. Leerink Partnrs upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a report on Tuesday, November 12th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and issued a $50.00 price target on shares of Bristol-Myers Squibb in a report on Friday, October 18th. Two research analysts have rated the stock with a sell rating, fourteen have given a hold rating, two have assigned a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $54.29.

Insider Transactions at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat purchased 1,830 shares of the company’s stock in a transaction dated Friday, November 1st. The stock was purchased at an average price of $54.67 per share, with a total value of $100,046.10. Following the completion of the purchase, the executive vice president now owns 62,109 shares of the company’s stock, valued at approximately $3,395,499.03. The trade was a 3.04 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Phil M. Holzer sold 700 shares of Bristol-Myers Squibb stock in a transaction that occurred on Monday, November 4th. The stock was sold at an average price of $55.62, for a total value of $38,934.00. Following the completion of the sale, the senior vice president now owns 11,760 shares of the company’s stock, valued at approximately $654,091.20. The trade was a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.09% of the company’s stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.